Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population ‐based cohort study in Taiwan

ConclusionBiologics used in RA patients have been shown to have a beneficial impact on improving clinical outcomes, including decreased risks of death and stroke. The economic burden from costs of biologics may be alleviated by improving outcomes.
Source: International Journal of Rheumatic Diseases - Category: Rheumatology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

ObjectiveRheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVEs in RA patients.MethodsA randomized, double ‐blind, placebo‐controlled trial was designed to detect a 32% CVE risk reduction based on an estimated 1.6% per annum event rate with 80% power atP50 years or with a disease duration of>10 years who did not have clinical atherosclerosis, diabetes, or myopathy received atorvastatin 40 mg daily or matching placebo. The primary end point was a c...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
Conclusion: Our meta-analysis results revealed higher cardiovascular risk in OA patients. This highlights the importance of cardiovascular risk factor management in OA.
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
In this study, plasma cfDNA was extracted from the plasma of cardiac disease patients and the cfDNA fragment distribution as well as the relationships between cfDNA concentration and deoxyribonuclease I (DNase I) activity enzyme implicated in double-stranded DNA processing were examined. Results revealed that the cfDNA concentrations in patients with MI and cardiac angina were significantly higher than that in healthy control subjects. Microchip electrophoresis of plasma cfDNA revealed a single fragment (150–200 bp) in some healthy control subjects and three fragments (150–200 bp, 300–400 bp, and 50...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
In this study, plasma cfDNA was extracted from the plasma of cardiac disease patients and the cfDNA fragment distribution as well as the relationships between cfDNA concentration and deoxyribonuclease I (DNase I) activity enzyme implicated in double-stranded DNA processing were examined. Results revealed that the cfDNA concentrations in patients with MI and cardiac angina were significantly higher than that in healthy control subjects. Microchip electrophoresis of plasma cfDNA revealed a single fragment (150-200 bp) in some healthy control subjects and three fragments (150-200 bp, 300-400 bp, and 500-600 bp) in all...
Source: International Journal of Clinical Chemistry - Category: Chemistry Authors: Tags: Clin Chim Acta Source Type: research
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In conclusion, activation of pDCs and glandular epithelial cells by external or endogenous triggers induce the production of type I IFN through TLRs. Type I IFN will lead to BAFF release and activation of B cells with consequent auto-antibody production. Moreover, type I IFN may directly activate T cells which secrete pro-inflammatory cytokines, thus contributing to induce a pro-inflammatory environment. In this scenario, a feedback loop may be postulated between IFN-α production and immune complex formation which will amplify the effect of activated type I IFN system on onset or perpetuation of SS. Role of Chemokin...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionIn this post ‐hoc analysis, after 24 weeks of tofacitinib, increased HDL‐c, but not increases in LDL‐c or TC, appeared to be associated with lower future MACE risk. Further data are needed to test the cardiovascular safety of tofacitinib.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Full Length Source Type: research
Conclusions In recent years, there have been many advances in the understanding of the molecular basis for vascular involvement in APS, but many areas need to be further investigated, in particular the association between altered genetic/epigenetic profiles, autoantibodies and clinical manifestations, and the effectiveness of new therapeutic strategies. It would be interesting to apply next generation sequencing technologies like RNA-Seq along with GWAS to screen both, the gene profile and the whole transcriptome of large cohorts of primary APS patients, in order to reveal the mutations/polymorphisms, post-transcriptiona...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractObjectiveRheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVE in RA patients.MethodsRandomized, double ‐blind, placebo‐controlled trial designed for 80% power at p50 years or with RA duration>10 years; without clinical atherosclerosis, diabetes, or myopathy; received atorvastatin 40mg daily or matching placebo. Primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, transient ischemic attack, or any arteri...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Full Length Source Type: research
Lilly Rocha was 37 years old in 2008 when she began having strange symptoms. When people asked her questions, she knew the answers but couldn’t articulate them. A tingling sensation on her left breast became painful. She thought she might have breast cancer, but her doctor assured her she was just experiencing stress from her demanding job. Her symptoms continued to get worse, and doctors continued to dismiss her. Three months later, at work, she became seriously ill. Luckily, her boss recognized the symptoms—chest and jaw pain and numbness in her left hand—and drove her to the nearest emergency room, whe...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized heart health Source Type: news
More News: Arthritis | Cardiology | Cardiovascular | Databases & Libraries | Health Insurance | Heart | Heart Attack | Insurance | Restasis | Rheumatoid Arthritis | Rheumatology | Stroke | Study | Taiwan Health